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Pre-clinical evaluation of contraceptive steroids: regulatory
requirements and scientific expectations*
G.Zbinden
Institute of Toxicology, Swiss Federal Institute of Technology and
University of Zurich, Schwerzenbach, Switzerland
The development of new contraceptive steroids placed great
pressures on regulatory agencies. There was insufficient time
to develop a novel pre-clinical safety evaluation, hence their
toxkity in animals was assessed as with other drugs. The ap-
proach of regulatory agencies to toxicity and carcinogenicity
testing of these steroids are discussed and evaluated.
Introduction
When the new steroidal contraceptives were introduced into prac-
tice, it soon became apparent that they were highly effective,
surprisingly well tolerated and dependable even on long-term use.
Thus, it was easy to predict that these agents would be taken
by a large fraction of the healthy female population and for con-
siderable periods of time.
In contrast to other chemicals to which large segments of the
population are exposed, e.g. environmental pollutants and food
additives, steroidal contraceptives are ingested in relatively high,
pharmacologically active doses, leading to a variety of changes
in sex hormone-dependent organs, metabolic alterations, and cer-
tain cardiovascular and neurobehavioural dysfunctions. Although
diese effects were rarely of such a magnitude that the use of
contraceptive steroids had to be discontinued, they gave rise to
much concern, because their long-range consequences were un-
known. Table I summarizes some of the early effects of steroidal
contraceptives, and the changes that had to be considered as
potential hazards on long-term treatment.
Based on these scientific speculations, it was decided that long-
term toxicity studies in laboratory animals were necessary to
assure the safety of women taking contraceptive steroids for many
years. However, because the drugs were already in the market
place, a unique situation developed: experience of the toxic poten-
tial of the drugs in humans was accumulated simultaneously with
the data from long-term animal safety studies. Whenever a distur-
bing finding was made in an animal experiment, it had immediate
consequences for the use of contraceptive steroids in clinical prac-
tice. An example is the detection of mammary nodules in beagle
bitches which led to the withdrawal of certain contraceptives and
to extensive epidemiological surveys. Vice versa, clinical findings
of unexpected adverse responses in women often brought about
the request for development of new animal models. For exam-
ple, the discovery of an increased risk for thromboembolic com-
plications in contraceptive users stimulated much research on
assay systems for detection of hypercoagulability in laboratory
animals.
'Based on a paper presented at the conference on Post-Marketing Surveillance
of Drugs used in Fertility Regulation, organized by the International Committee
for Research in Reproduction, Leuven, 17-19 October, 1985.
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Pre-clinical evaluation
Regulatory requirements
The rapid development of new contraceptive steroids and their
widespread acceptance in the population put regulatory agencies
under considerable pressure. A novel approach to pre-clinical
safety evaluation, especially tailored to orally active steroids,
could not be developed, because there was neither enough time,
nor was the science of comparative endocrinology far enough
advanced. For this reason, regulatory agencies decided to request
essentially the same kind of animal toxicity studies that were
routinely gathered with other drugs. A survey of regulatory re-
quirements in selected countries was recendy published by Rowe
(1983).
Because the long-term use of contraceptive steroids was ex-
pected to be a frequent occurrence, the possibility of carcinogenic
effects was particularly considered, hi 1964 the Committee on
Safety of Medicines of the UK (CSM) initiated a review of ex-
isting data on carcinogenicity of contraceptive steroids. Based
on findings of liver tumours in rats induced with mestranol, the
Committee decided in 1966 to request carcinogenicity studies in
rats and mice for all marketed and new oral contraceptives (CSM,
1972).
In the USA, a new policy on animal studies widi steroidal
contraceptives was announced by the Food and Drug Administra-
tion (FDA) in the late 1960s. It specified the kind of animal safety
data necessary for initiation of the three phases of clinical trials
and for the submission of a new drug application (Goldenthal,
1969). These guidelines are summarized in Table II. In addition
to a 2-year carcinogenicity experiment in rats, FDA demanded
7-year carcinogenicity studies in female beagle dogs and 10-year
carcinogenicity studies in female monkeys (FDA, 1968).
A particular feature of the FDA guidelines was the specifica-
tion of the doses to be used in the long-term experiments in dogs
and monkeys. It was decided that die dose selection had to be
based on the human dose given as prescribed clinically (2, 10
and 25 the anticipated human doses in beagle dogs, and 2, 10
and 50 times the anticipated human dose in monkeys).
Not all regulatory agencies, by far, insisted on the long-term
experiments with beagle dogs and monkeys. However, since the
USA is the most important market for oral contraceptives, prac-
tically all existing and many new contraceptive steroids were,
and still are, submitted to the long-term studies in these two
species. In developing countries which have limited toxicological
expertise, the drug regulatory agencies prefer to register those
drugs which are introduced in the markets of the country of origin
and preferably also in the USA. Thus, the FDA guidelines are
often accepted as the most desirable standard.
At present, the 7-year dog and 10-year monkey studies are
mandatory in the USA and Canada. In Western Europe, steroidal
contraceptives fall under the general clause of drugs administered
for prolonged periods of time. This implies that carcinogenicity
studies in one or two rodent species are required.
Scientific expectations
Since I have not taken part in the decision making process on
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Table I. Selected effects of contraceptive steroids and potential consequences of long-term use
Organ Effects Potential long-term consequences
Ovary
Uterus
Mammary gland
Liver
Pancreas
Cardiovascular system
Nervous system
Inhibition of ovulation
Amenorrhoea
Tenderness, galactorrhoea
Functional disturbances
Disturbance of glucose tolerance
Hyperlipidaemia, transient blood pressure elevation, oedema
Psychic lability, anxiety, migraine
Cyst formation
Cystic hyperplasia, endometritis, carcinoma
Fibrocystic hyperplasia, adenoma, carcinoma
Icterus, biliary cirrhosis, gall bladder disease, coagulopathy, tumour
Diabetes mellitus
Atherosclerosis, hypertension, myocardial infarct
Mental depression, stroke
Table D. FDA guidelines for toxicity testing of steroidal contraceptives
Extent of clinical
studies
Animal toxicity requirements
Phase I
Phase II
Phase III
New drug application
90-day toxicity in rats, dogs and monkeys
1-year toxicity in rats, dogs and monkeys; fertility
and reproductive performance in female rodents;
teratology in rats and rabbits
2-year toxicity in rats, dogs and monkeys; 7-year
dog and 10-year monkey toxicity started, peri- and
postnatal toxicity in rodents; fertility and reproduc-
tive performance in male rodents
up-to-date progress reports on long-term dog and
monkey studies
See Goldenthal (1969).
Table ID. Parameters monitored in 10-year toxicity studies in monkeys
(FDA, 1968)
General toxicity
Sex and related hormones
Metabolism
Pathomorphology
Haemostatic system (optional)
appearance, body weight
menstrual cycle, vaginal cytology, urinary
17-hydroxy and 17-ketosteroid excretion,
breast examinations
fasting blood sugar, if changed, glucose
tolerance
all organs, special emphasis on sexual and
endocrine organs and blood vessels
prothrombin time, platelet count, Stypven
time, regular and activated thromboplastin
time, fibrinogen
the toxicological guidelines of steroidal contraceptives, it is dif-
ficult for me to speculate about the scientific information which
the regulatory agencies hoped to obtain. Some insight can,
perhaps, be gleaned from the recommended protocols for the
long-term studies in dogs and monkeys. As an example, the end-
points which, according to the FDA recommendations, should
be investigated with special care in the monkey studies, are sum-
marized in Table HI.
From this list, three kinds of toxicological targets can be iden-
tified, namely: (i) general toxicity and organ-directed toxicity not
related to hormonal and metabolic effects; (ii) toxicity related
to hormonal effects; (iii) toxicity related to metabolic effects. For
the first kind of adverse effects, the rather unsophisticated stan-
dard procedures used for other drugs and chemicals were deem-
ed sufficient. Apparently, it was expected that direct toxicity
affecting organs such as liver, bone marrow and kidney would
manifest itself in the course of routine animal studies. No ef-
forts were made to gain more detailed information on several
additional potential targets such as the neurobehavioural func-
tions, the musculoskeletal and immunological systems and the
cardiovascular functions.
Exceptions were the potential adverse effects on the structure
of the blood vessels and the function of the haemostatic system.
The recommended investigations (detailed histopathology of blood
vessels and a set of routine coagulation assays) were issued as
a response to epidemiological evidence of increased risk for
thromboembolic complications in a small percentage of users of
contraceptive steroids. Although nothing was known about the
possible mechanisms of this complication, the recommendations
for laboratory investigations were very specific and taken right
off the shelf of the routine coagulation laboratory. All these tests
were originally developed to detect coagulopathies of various
kinds (Zbinden, 1976), but the scientific expectations apparent-
ly were that they would work equally well for the demonstration
of hypercoagulable states and impending thrombosis in animals.
It comes hardly as a surprise that the procedures demanded by
the FDA proved to be of little use. Only after extensive research
on the biological mechanisms of drug-induced thromboembolism
was it possible to develop realistic tests for the assessment of
the thrombogenicity of steroidal contraceptives (Wessler, 1983).
That the majority of adverse effects of steroidal contraceptives
were directly caused by the hormonal effects of the drugs, was
well recognized. Nevertheless, the investigations required to
assess these properties in the animal experiments appear to be
very limited in scope (Table HI). It can hardly be expected that
monthly palpations of the breast, semi-annual vaginal cytology
and yearly urinary ketosteroid determinations would suffice to
detect all relevant changes in the endocrine equilibrium. Thus,
it is difficult to understand why such exceedingly extensive studies
as a 10-year carcinogenicity experiment on > 60 monkeys were
demanded without making use of all the available techniques for
monitoring endocrine regulation and target organ responses.
A word should be said about the dose selection for long-term
carcinogenicity studies. The request for high-dose treatments was
most certainly motivated by the desire to detect even weak and
rare toxic effects. This practice was taken over from the stan-
dard procedures for drug toxicity testing and carcinogenicity
bioassays with pharmacologically inert substances. Unfortunately,
the approach did not take into consideration many basic physio-
logical facts, such as: (i) in mammals, the same reproductive pro-
cesses are regulated, in part, by different sexual hormones and
different interactions with peptide hormones; (ii) the effects of
hormones and hormone-like drugs differ in various mammalian
species; (iii) in mammals hormones are secreted in different
amounts; (iv) the hormone sensitivity of target organs differs in
mammalian species; (v) continued overstimulation of endocrine
and endocrine-dependent organs often leads to hyperplastic and
neoplastic responses (Williams, 1982).
If the marked species differences are not taken into account
for dose selection, many erroneous results may ensue. For ex-
ample, the optimal ratio of oestrogen to progestogen for the rat
is 1:10 000 to 1:20 000 and for women 1:50 to 100. If these
4/Y?
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Table FV. Testing strategies for new contraceptive steroids
1. Detection and characterization of toxic properties per se
2. Characterization of the pharmacodynamic (endocrinological) and metabolic
effects in suitable animal species
3. Target organ response to repeated administrations of effective and small
multiples of effective doses in suitable animal species
4. Pharmacokinetics and metabolic fate of test drug in suitable animal species
5. Detection of mutagenjc and teratogenic properties
6. Characterization of pharmacodynamic (endocrinological) and metabolic pro-
perties in humans at effective doses
7. Pharmacokinetic and metabolic fate of test drugs in humans
8. Target organ responses to prolonged administration of effective doses in
humans
differences are not considered, and if the optimal human ratio
is used in a rat toxicity study, virtually only the oestrogen com-
ponent can exert an effect (Neumann and Graf, 1979).
It is also important to recognize that hormones act differently
according to the dose. For example, in the rat, oestrogens
stimulate prolactin release, and progestogens act synergistically
or antagonistically, depending on the dose (Neumann and Graf,
1979). It must also be noted that the pharmacokinetics of steroidal
contraceptives differ markedly among species. For example,
elimination of many progestogens in the dog is much slower than
in man. For other drugs such as chlormadinone, the elimination
half-life in dogs and women is comparable, but in the dog, the
volume of distribution is much larger. Megestrol acetate is ex-
creted by the biliary route in the dog, but in women mainly in
the urine (El Etreby and Graf, 1979).
In view of these and many other biological species differences
which have come to light in recent years, one must conclude that
the scientific expectations for the long-term animal studies were
mainly a result of wishful thinking rather than a consequence
of a well reasoned approach to an important public health
problem.
Of the metabolic changes induced by steroidal contraceptives,
only the possibility of diabetogenic effects were considered.
Clinical experience has since shown that other areas should also
be investigated. Among these are water and electrolyte balance
and lipid metabolism.
Conclusions
Over the past 20 years, a considerable number of steroidal contra-
ceptives have undergone extensive animal toxicity testing. The
approach originally required by regulatory agencies, i.e. high-
dose and long-term carcinogenicity studies in rodents, beagle dogs
and monkeys, has resulted in a large number of experiments in
which hyperplastic and neoplastic responses developed in a varie-
ty of organs. For many of the tumours induced in rodents, not
only marked species differences but also strain differences were
observed. From a recent review by Beier et al. (1983) it is evi-
dent that many additional factors such as living conditions, age,
sex, biodynamics of the test drug, and route, duration and fre-
quency of administration play an important role. Therefore, it
is unlikely that such experiments using rodents will yield much
relevant data for the safety assessment of new steroidal contra-
ceptives. The same conclusion had already been reached in 1972
by the CSM.
In the dog, the appearance of mammary tumours has caused
some anxiety. However, extensive studies of the phenomenon
have demonstrated basic differences between dog and man in the
response of the endocrine system to contraceptive steroids. Thus,
it is highly questionable that the beagle model, at least as far as
mammary tumours are concerned, has fulfilled the scientific ex-
pectations. Many toxicologists are now of the opinion that its
further use would be without sound scientific justification (El
Etreby and Graf, 1979; Beier et al., 1983).
The results of the long-term carcinogenicity studies in monkeys
are only now being evaluated. So far, it seems that very few
tumours are induced in this species. This indicates that the results
of carcinogenicity studies in the monkeys are in good agreement
with the clinical experience in man, despite the high doses used.
The observation of endometrial carcinoma in two monkeys treated
for 10 years with a high dose of medroxyprogesterone acetate
has recently caused concern (Beier et al., 1983). The results of
further studies in monkeys exposed to other steroids will have
to be awaited, before the significance of this finding can be
assessed.
In view of the practical experience accumulated in animal
studies, and the knowledge of the hazards of steroidal contra-
ceptives in humans, it is necessary to reconsider the basic ap-
proach to safety testing of new fertility-regulating agents. Because
of the many physiological and pharmacokinetic differences be-
tween laboratory animals and man, the straightforward applica-
tion of routine toxicity procedures has given too many 'false-
positive' results. It is believed that the medical community would
be served better if the biological characteristics of new compounds
were studied in specially designed experimental systems. The
basic strategy for such an approach is summarized in Table IV.
In particular, the endocrinological profile of new agents should
be investigated carefully in several animal species whose target
organ responsiveness to natural hormones and synthetic
derivatives is well known. In addition, the pharmacokinetic
behaviour of the test substances must be investigated, and the
target organ responses must always be related to the plasma con-
centrations necessary to induce the change.
Whenever combinations of two or more steroids are tested,
the ratio of the components must be adjusted to the physiological
response of the species selected. It may often be different from
the ratio proposed for the use in humans. Other toxicological
properties which should be assayed in special test systems are
mutagenicity and teratogenicity. In special cases, binding studies
to cellular macromolecules and test systems designed to detect
transforming or tumour-promoting activities may add useful in-
formation.
As with all new drugs, the possibility that a contraceptive
steroid may be toxic per se, and could cause organ damage by
mechanisms unrelated to its hormonal properties, must be con-
sidered. For the detection of such effects, a subchronic (90 day)
standard toxicological experiment, in one or two animal species
showing endocrinological responsiveness to the test drug that is
comparable to man, should be sufficient. In such experiments,
the metabolic effects should receive particular attention.
Finally, a determined effort must be made to monitor target
organ responses in patients, not only in the subjects used in early
clinical trials, but also in patients taking the drug for prolonged
periods of time. Thus, the safe use of new contraceptive steroids
clearly becomes a shared responsibility of the toxicologists and
the clinical investigators. My scientific expectations are that this
approach will significantly improve our ability to predict human
hazards. In addition, it is likely to accelerate the development
of new fertility-regulating drugs. It is hoped that regulatory agen-
cies will give these safety testing strategies a chance to prove
their usefulness.
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